MPMichael A. Platt

Michael A. Platt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael A. Platt has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain

    by Michael A. Platt, Ekaterina Kot, Louise A. W. Martin, Antoine L. D. Wallabrègue, Liwen Song, Alistair M. Boyd, Lizbé Koekemoer, Ester M. Hammond, Stuart J. Conway

    TRIM24 is an epigenetic transcriptional coregulator that “reads” KMe 3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small‐molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off‐target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe 3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3‐mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide‐drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate ( k off ), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.


  • Open Access

    Development and Evaluation of High Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain

    by Michael Platt, Ekaterina Kot, Louise Martin, Antoine Wallabrègue, Liwen Song, Alistair Boyd, Lizbé Koekemoer, Ester Hammond, Stuart Conway

    TRIM24 is an epigenetic transcriptional coregulator that ‘reads’ KMe3 and KAc histone modifications via its tandem plant homeodomain (PHD) and bromodomain (BRD), respectively. The PHD and BRD are potential therapeutic targets due to the roles of TRIM24 in breast cancer progression. However, there are currently no small molecule ligands for the PHD, and existing TRIM24 BRD inhibitors lack selectivity over the main off-target, BRPF1. Here, we report the development of the first bivalent tool molecules capable of simultaneously engaging both the TRIM24 PHD and BRD. Key to this strategy was the identification of effective KMe3 bioisosteres that enhance H3 peptide binding to the TRIM24 PHD. The most promising of these was incorporated into a nine amino acid H3-mimicking peptide, and linked to a TRIM24 BRD ligand. The resulting peptide-drug conjugates (PDCs) bind to TRIM24 with picomolar affinity and a slow dissociation rate (koff), which is driven by an in cis bivalent binding mode. Although the PDCs showed limited effects on breast cancer cell proliferation in vitro, this work underscores their potential as tools for studying previously unliganded reader domains and consequently advancing our understanding of multivalent epigenetic regulation in disease.

  • Open Access

    Advancing atmospheric solids analysis probe mass spectrometry applications: a multifaceted approach to optimising clinical data set generation

    by Liwen Song, Jasmine G. Reese, Michael A. Platt, Claire Lewis, Annabel S. J. Eardley-Brunt, Bo Sun, Olaf Ansorge, Claire Vallance

    We assess the impact of various experimental factors on ASAP-MS spectra, and make a series of recommendations to optimise the reliability and reproducibility of such measurements in clinical settings.